4//SEC Filing
BRIMBLECOMBE ROGER W 4
Accession 0000875320-10-000015
CIK 0000875320other
Filed
Mar 15, 8:00 PM ET
Accepted
Mar 16, 4:18 PM ET
Size
9.1 KB
Accession
0000875320-10-000015
Insider Transaction Report
Form 4
BRIMBLECOMBE ROGER W
Director
Transactions
- Exercise/Conversion
Common Stock
2010-03-15$38.44/sh+10,000$384,400→ 10,000 total - Sale
Common Stock
2010-03-15$43.10/sh−10,000$431,000→ 0 total - Exercise/Conversion
Stock Option
2010-03-15−10,000→ 0 totalExercise: $38.44From: 2000-06-01Exp: 2010-05-31→ Common Stock (10,000 underlying)
Footnotes (4)
- [F1]Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1.
- [F2]Open market sales reported on this line occurred at a weighted average price of $43.10 (range $42.80 to $43.52).
- [F3]Dr. Brimblecombe undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F4]Right to buy under under 1996 Stock and Option Plan, fully vested on grant date, 6/1/2000.
Documents
Issuer
VERTEX PHARMACEUTICALS INC / MA
CIK 0000875320
Entity typeother
Related Parties
1- filerCIK 0001197034
Filing Metadata
- Form type
- 4
- Filed
- Mar 15, 8:00 PM ET
- Accepted
- Mar 16, 4:18 PM ET
- Size
- 9.1 KB